Relief Therapeutics Holding SA (RLF.SW)
- Previous Close
1.2150 - Open
1.2150 - Bid 1.2600 x --
- Ask 1.3250 x --
- Day's Range
1.2000 - 1.3250 - 52 Week Range
1.2000 - 15.0000 - Volume
25,908 - Avg. Volume
15,665 - Market Cap (intraday)
15.395M - Beta (5Y Monthly) -14.37
- PE Ratio (TTM)
-- - EPS (TTM)
-7.3500 - Earnings Date Apr 19, 2024 - Apr 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland.
www.relieftherapeutics.comRecent News: RLF.SW
Performance Overview: RLF.SW
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RLF.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RLF.SW
Valuation Measures
Market Cap
15.40M
Enterprise Value
5.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35
Price/Book (mrq)
0.16
Enterprise Value/Revenue
1.00
Enterprise Value/EBITDA
-0.07
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.55%
Return on Equity (ttm)
-63.17%
Revenue (ttm)
5.86M
Net Income Avi to Common (ttm)
-80.79M
Diluted EPS (ttm)
-7.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
12.8M
Total Debt/Equity (mrq)
4.82%
Levered Free Cash Flow (ttm)
-16.67M